BioMarin

YTD

ALL

Trade BioMarin 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMRN

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307.

CEO

Alexander Hardy

CEOAlexander Hardy

Employees

3,221

Employees3,221

Headquarters

San Rafael, California

HeadquartersSan Rafael, California

Founded

1997

Founded1997

Employees

3,221

Employees3,221

BMRN Key Statistics

Market cap

10.12B

Market cap10.12B

Price-Earnings ratio

38.58

Price-Earnings ratio38.58

Dividend yield

—

Dividend yield—

Average volume

2.47M

Average volume2.47M

High today

$53.31

High today$53.31

Low today

$52.20

Low today$52.20

Open price

$52.78

Open price$52.78

Volume

2.33M

Volume2.33M

52 Week high

$66.28

52 Week high$66.28

52 Week low

$49.26

52 Week low$49.26

Stock Snapshot

With a market cap of 10.12B, BioMarin(BMRN) trades at $52.38. The stock has a price-to-earnings ratio of 38.58.

During the trading session on 2026-05-28, BioMarin(BMRN) shares reached a daily high of $53.31 and a low of $52.20. At a current price of $52.38, the stock is +0.3% higher than the low and still -1.7% under the high.

Trading activity shows a volume of 2.33M, compared to an average daily volume of 2.47M.

The stock's 52-week range extends from a low of $49.26 to a high of $66.28.

BMRN News

Simply Wall St 1d

A Look At BioMarin Pharmaceutical Valuation After Positive Voxzogo Phase 3 Trial Results

BioMarin Pharmaceutical (BMRN) is back in focus after its Phase 3 CANOPY-HCH-3 trial of Voxzogo in children with hypochondroplasia met primary and key secondary...

Simply Wall St 3d

Why BioMarin Is Up 8.9% After VOXZOGO’s Phase 3 Success In Hypochondroplasia Trial

Earlier in May 2026, BioMarin reported that its Phase 3 CANOPY-HCH-3 trial of VOXZOGO in children with hypochondroplasia met its primary endpoint, showing a sta...

TipRanks 6d

BioMarin price target lowered to $111 from $116 at Canaccord

Canaccord lowered the firm’s price target on BioMarin (BMRN) to $111 from $116 and keeps a Buy rating on the shares. The firm updated its model following the ne...

Analyst ratings

79%

of 29 ratings

Buy

79.3%

Hold

20.7%

Sell

More BMRN News

TipRanks 7d

Buy Rating Reaffirmed on BioMarin as Voxzogo Skeletal Disorder Opportunity Expands; $94 Price Target Maintained

Wedbush analyst Yun Zhong maintained a Buy rating on BioMarin Pharmaceutical today and set a price target of $94.00. Meet Samuel – Your Personal Investing Proph...

People also own

Based on the portfolios of people who own BMRN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.